Meet the Team

Richard J. Wenstrup, MD Chief Medical Officer

Richard J. Wenstrup, MD joins Epic Sciences as Chief Medical Officer, bringing more than 25 years of clinical leadership experience managing life science companies before joining industry from academia.

Dr. Wenstrup was previously chief medical officer for Oxford Immunotec, Inc., where he oversaw research and development, product development, regulatory, medical and clinical affairs. From 2006-2017, he served as chief medical officer for Myriad Genetics, where he built and led the clinical and medical affairs team to support a multi-fold increase in revenue during his tenure. Dr. Wenstrup was actively involved in the company’s product development, M&A and in-licensing activities.‍

Prior to joining industry, Dr. Wenstrup served as a tenured professor of pediatrics in human genetics at Cincinnati Children’s Hospital Medical Center and as a tenured professor of biomedical engineering at the University of Cincinnati, where he earned his medical degree. He was internationally recognized as a leader in inherited disorders of the musculoskeletal system and was principal investigator on multiple research grants from the National Institutes of Health and the FDA Orphan Products Grant Program. As an entrepreneur, Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children’s Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.

Lloyd Sanders President and Chief Executive Officer

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers.

Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer).

Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.

Chockalingam “Palani” Palaniappan, PhD Chief Technology Officer

Chockalingam “Palani” Palaniappan is the chief technology officer at Epic Sciences. An accomplished global life sciences innovation executive with more than 20 years of global leadership experience across three multinational corporations, GE Healthcare, Life Technologies, and Terumo BCT, delivering over $500M in career revenue. Palani’s proven track record in managing products, people and process spans diverse fields from life science tool companies to the MedTech Industry. He has helped architect many transformative products at the interface of science and technology for scientific and clinical applications including genomics, proteomics, cell biology tools to patient connected engineering devices in health.

Before joining Epic Sciences, Palani was the executive vice president of Innovation and Development and a board member of the Terumo Global Blood Management at Terumo BCT, a global leader in blood management, therapeutic apheresis, cell therapy and regenerative medicine. Prior to this role, he served as the vice president for Research and Development for Cellular Analysis at Life Technologies. Preceding that, he was the head of Molecular Diagnostics for the Amersham Life Sciences unit of GE Healthcare.  Palani has a PhD in the field of biological sciences from Northern Illinois University, followed on by a post-doctoral fellowship at the University of Rochester in HIV biology.

Joel Smith Chief Financial Officer & General Counsel

Joel Smith serves as Chief Financial Officer and General Counsel at Epic Sciences.

A veteran legal professional with more than 20 years of experience in the life sciences and biopharmaceutical industries, Mr. Smith brings a breadth of knowledge in strategic corporate development, complex commercial transactions, licensing, securities law, corporate governance and regulatory compliance. Smith has served as a senior executive and general counsel for a number of biotechnology and life sciences companies, including BioQ, Triad Therapeutics, and Sientra, Inc. At Sientra, Smith was responsible for all of its legal affairs including corporate compliance, commercialization policies, and intellectual property. He was a primary contributor to its premarket application for FDA approval of its implants and in the preparation of the prospectus used in its initial public offering on Nasdaq.

Most recently, Smith was the managing counsel of Qualcomm Life, the medical device subsidiary of Qualcomm where he and his team supported global sales and business development teams.

Smith earned his Juris Doctorate, cum laude, and a Master of Business Administration, with highest distinction, from the University of Michigan, as well as a Bachelor of Science in Cellular and Molecular Biology and Economics. He is a member of the State Bar of California.